{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '5', 'Version Date: 07/22/2019', 'Enrolling 2 patients/month, it is estimated to require 3 years to complete accrual to a', 'maximum of 70 patients, a maximum of 63 evaluable patients allowing for a small', 'number (7) of inevaluable patients.']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '6', 'Version Date: 07/22/2019', 'TABLE OF CONTENTS', 'PR\u00c9CIS', '3', 'TABLE OF CONTENTS', '6', '1', 'INTRODUCTION', '12', '1.1', 'Study Objectives', '12', '1.1.1', 'Primary Objective', '12', '1.1.2', 'Secondary', '12', '1.1.3', 'Exploratory', '12', '2', 'BACKGROUND AND RATIONALE', '12', '2.1.1', 'Background', '12', '2.1.2', 'Gastrointestinal stromal tumors', '12', '2.1.3', 'Pheochromocytoma and Paraganglioma', '13', '2.1.4', 'Renal Cell Carcinoma', '13', '2.1.5', 'SGI-110', '13', '2.1.6', 'Health-Related Quality of Life and Patient-Reported Symptoms', '15', '2.1.7', 'Rationa le', '16', '3', 'PATIENT SELECTION', '16', '3.1', 'Eligibility Criteria', '16', '3.1.1', 'Inclusion Criteria:', '16', '3.1.2', 'Exclusion Criteria', '18', '4', 'RECRUITMENT AND REGISTRATION', '19', '4.1 Recruitment', '19', '4.2', 'Screening Evaluation', '19', '4.2.1', 'History and physical examination', '19', '4.2.2', 'Imaging evaluation', '19', '4.2.3', 'Hematology', '19', '4.2.4', 'Chemistries', '20', '4.2.5', 'Urine or serum pregnancy test for all females of childbearing potential', '20', '4.2.6', 'Pathologic/Tissue Evaluation', '20', '4.2.7', 'For patients with PHEO/PGL', '20', '4.3', 'Registration Procedures', '20', '4.3.1', 'IWRS', '20', '4.3.2', 'OPEN/IWRS', '20', '4.3.3', 'OPEN/IWRS User Requirements', '21', '4.3.4', 'OPEN/IWRS Questions?', '21']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '7', 'Version Date: 07/22/2019', '4.4', 'Local Registration for NCI CCR', '21', '5', 'STUDY IMPLEMENTATION', '21', '5.1', 'Study Design', '21', '5.2', 'Drug Administration', '22', '5.3', 'Dose Modifications', '22', '5.4', 'Questionnaires (Appendix III and Appendix IV)', '23', '5.4.1', 'PROMIS', '23', '5.4.2', 'Distress Rating Tool', '23', '5.5', 'On-Study Evaluation', '23', '5.5.1', 'Baseline Assessment', '23', '5.6', 'Study Calendar', '24', '5.7', 'Criteria for Removal from Protocol Therapy and Off Study Criteria', '27', '5.7.1', 'Criteria for removal from protocol therapy', '27', '5.7.2', 'Off-Study Criteria', '27', '5.7.3', 'Off Protocol Therapy and Off-Study Procedure', '27', '6', 'CONCOMITANT MEDICATIONS/MEASURES', '27', '6.1', 'Injection Site Reactions', '27', '6.2 Mucositis', '28', '6.3', 'Diarrhea', '28', '7', 'BIOSPECIMEN COLLECTION', '28', '7.1', 'Correlative Studies for Research/Pharmacokinetic Studies', '28', '7.1.1', 'Pharmacokinetics', '28', '7.1.2', 'Expression of SDH complex subunits and FH', '29', '7.1.3', 'DNA hyper-methylation', '29', '7.1.4', 'NY-ESO-1 expression', '29', '7.1.5', 'Serum and Urine Concentrations of glycolytic metabolites', '29', '7.2', 'Sample Storage, Tracking and Disposition', '31', '7.2.1', 'Sample Storage and Destruction', '31', '8', 'MEASUREMENT OF EFFECT', '32', '8.1', 'Definitions', '32', '8.2', 'Disease Parameters', '33', '8.2.1', 'Methods for Evaluation of Measurable Disease', '34', '8.2.2', 'Response Criteria', '36', '8.2.3', 'Duration of Response', '37', '9', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', '38']\n\n###\n\n", "completion": "END"}